A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- Fact check: Exposure to aluminum through food does not cause neural issues or canceron June 23, 2020 at 7:06 am
A widely shared article claims heat causes aluminum to leach into food, which then leads to health issues. This isn't entirely true.
- Two doses of Oxford University Covid-19 vaccine produces stronger immune response than oneon June 23, 2020 at 6:00 am
In trials on pigs researchers found the vaccine being developed by scientists at Oxford appears to work better in a two-part 'prime' and 'boost' dosage - the same way the MMR jab is given.
- POLITICO Playbook: Doug Jones’ new ad, and Dems readying to block police reformon June 23, 2020 at 3:58 am
NEW … PLAYBOOK SNEAK PEEK: Sen. DOUG JONES (D-Ala.) is going up on statewide television with his first TV ad: a new 30-second, straight-to-camera TV spot about racial justice. JONES’ most recent ...
- JCVI includes dementia in priority groups for COVID-19 vaccinationon June 19, 2020 at 7:29 am
The Joint Committee on Vaccination and Immunisation (JCVI) has published interim advice on priority groups for COVID-19 vaccination ...
- Priority list of who should get Covid-19 vaccine firston June 18, 2020 at 11:42 pm
Frontline healthcare workers, over-50s and people with underlying conditions should be prioritised if a Covid-19 vaccine is developed, new advice has recommended. Health and social care workers are ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Fauci Testifies: Hopeful For A Vaccine By Late 2020on June 23, 2020 at 6:35 pm
With coronavirus cases rising in about half the states, Dr. Anthony Fauci returned to Capitol Hill on Tuesday.
- Fauci optimistic about coronavirus vaccine, but warns pandemic is far from overon June 23, 2020 at 5:02 pm
Dr. Anthony Fauci and other health experts cautioned Congress on the recent surges in coronavirus cases and reaffirmed their commitment to increasing timely testing. Fauci also expressed optimism that ...
- Fauci provides update on COVID-19 vaccine trials | Raleigh News & Observeron June 23, 2020 at 4:06 pm
Speaking before a House committee hearing June 23, 2020, Dr. Anthony Fauci gives an update on what he calls a "major effort" to produce a COVID-19 coronavirus vaccine. He says one potential vaccine ...
- Anthony Fauci tells Congress coronavirus vaccine is coming, urges caution on rising infectionson June 23, 2020 at 2:31 pm
The vaccine could be ready by the end of the year, the government’s top infectious disease expert told a House committee Tuesday.
- The Economics Of Vaccine Pricingon June 23, 2020 at 1:59 pm
We all agree that we need a vaccine for COVID-19 — for public health, and to stop its devastating effects. And also because without one, it's going to be difficult for our economy to reopen fully. But ...